Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025ATLANTA, GA, GA / ACCESS Newswire / October 14, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathic disorders, today announces that Greg Duncan, Chief Executive Officer will participate at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 - 23, 2025 at the Hard Rock Hotel in New York City.
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics SummitATLANTA, GEORGIA / ACCESS Newswire / October 7, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today announced that its Chief Medical Officer will present an overview of the Halneuron®(tetrodotoxin) pain management research program at the 19th Annual Pain Therapeutics Summit on October 14, 2025.
